← All grants

Phased Innovation Awards in AIDS Vaccine Research (R21/R33)

National Institutes of Health · Opportunity PA-06-519

Who can apply

• State governments
• Public and State institutions of higher education
• Nonprofits with 501(c)(3), other than higher education
• Nonprofits without 501(c)(3)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Foreign institutions are not eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply. Applicants may submit more than one application, provided each application is scientifically distinct. Clinical trials or first-time-in human studies will not be supported under this FOA. (See . http://grants.nih.gov/grants/guide/notice-files/NOT-AI-05-021.html). Clinical research, including research that uses clinical specimens, is within the scope of this announcement.

About this opportunity

-Purpose. This program will support prophylactic vaccine research projects that are innovative, novel, may be high risk/high impact, and that exhibit the potential to advance AIDS prophylactic vaccine design or evaluation. All areas of investigation contributing to the development of an efficacious HIV/AIDS vaccine are welcome. Clinical trials will not be supported under this initiative. -Mechanism of Support. This FOA will utilize the NIH Phased Innovation (combined R21 [Phase I, Exploratory]/R33 [Phase II, Developmental]) grant mechanism. Awards will support milestone-driven exploratory/feasibility proof of concept studies (2 year R21 phase), with possible rapid transition to expanded development (2-3 year R33 phase). Initially funded R21 studies will be tested over two years via milestone completion, and eligible R21s will be further assessed for the R33 award. -Funds Available. Funding will be based on scientific and technical merit, program priorities, and availability of funds. The R21 award will be limited to $275,000 directs over the two year award period, and the R33 award will be limited to $300,000 in direct costs per annum. NIH anticipates that a maximum of fifty percent (50%) of the funded R21 phase awards will progress to the R33 award.

Apply on grants.gov →

Similar grants still open